PURPOSE To investigate the factors influencing EORTC QLQ-C30-derived EORTC QLU-C10D utility values across five cancer types (non-Hodgkin lymphoma, multiple myeloma, colorectal, thyroid, and prostate cancer) and a general population sample. METHODS Data from the Dutch population-based patient-reported outcomes following initial treatment and long-term evaluation of survivorship (PROFILES) registry collected between 2009 and 2012 were used. EORTC QLQ-C30 data were used to estimate utility values by applying the EORTC QLU-C10D instrument using Australian utility weights. Regression analyses were conducted, within and across cancer type, to examine the factors influencing utility values, including patient- and cancer-specific factors, as well as the EORTC QLQ-C30 scale/item scores. RESULTS The mean utility value for the total cancer sample was 0.791 (SD 0.201), significantly lower than that from the general population (0.865, SD 0.165). Multiple myeloma patients had the lowest utility value at 0.663 (SD 0.244). Physical functioning, pain and nausea and vomiting were the health-related quality of life (HRQoL) domains with the greatest impact on utility values; cognitive functioning and dyspnea had the lowest impact. Of the demographic and clinical factors, unemployment for reasons other than retirement, age older than 75 years, number of comorbidities, and experience of symptoms all had a statistically significant negative impact on utility values. CONCLUSIONS This study is one of the first to apply the EORTC QLU-C10D to a heterogeneous group of cancer patients. Results can be used to more efficiently target care towards factors influencing HRQoL. Furthermore, it enhances our understanding of how the EORTC QLU-C10D performs across cancer types, supporting its use in cost-utility analyses.

中文翻译：

---

评估癌症幸存者与健康相关的生活质量：影响EORTC QLU-C10D衍生效用值的因素。

目的探讨影响五种癌症类型（非霍奇金淋巴瘤，多发性骨髓瘤，结直肠癌，甲状腺癌和前列腺癌）和普通人群样本的影响EORTC QLQ-C30衍生EORTC QLU-C10D效用值的因素。方法使用荷兰人以患者为基础的患者初步治疗后的结果报告，并于2009年至2012年间收集了长期生存率评估（PROFILES）。通过使用澳大利亚实用权重应用EORTC QLU-C10D仪器，将EORTC QLQ-C30数据用于估算实用价值。在癌症类型之内和之间进行了回归分析，以检查影响效用值的因素，包括患者和癌症特异性因素，以及EORTC QLQ-C30量表/项目得分。结果总癌症样本的平均效用值为0。791（SD 0.201），明显低于一般人群（0.865，SD 0.165）。多发性骨髓瘤患者的效用值最低，为0.663（SD 0.244）。身体机能，疼痛，恶心和呕吐是与健康相关的生活质量（HRQoL）领域，对效用价值的影响最大；认知功能和呼吸困难的影响最小。在人口统计学和临床​​因素中，除退休以外的其他原因造成的失业，年龄超过75岁的合并症，合并症的数量以及症状的经历均对效用价值产生了统计上显着的负面影响。结论本研究是将EORTC QLU-C10D应用于异质性癌症患者的首批研究之一。结果可用于将治疗更有效地针对影响HRQoL的因素。此外，